Xeltis Hemodialysis Access Graft (aXess) US Study | MicrobiomeTrials← Back to trialsNCT06494631
Xeltis Hemodialysis Access Graft (aXess) US Study
ENROLLING_BY_INVITATIONNAINTERVENTIONAL
Trial Details
Start: 2024-11-11Est. Completion: 2028-01
Enrollment target: 140 participants Locations- AKDHC Medical Research Services, LLC, Phoenix, Arizona, United States
- AKDHC Medical Research Services, LLC, Tuscon, Arizona, United States
- Sarasota Memorial Hospital, Sarasota, Florida, United States
- Brigham and Women's Hospital, Boston, Massachusetts, United States
- Greenwood Leflore Hospital, Greenwood, Mississippi, United States
- Surgical Specialists of Charlotte, Charlotte, North Carolina, United States
- Flow Vascular, Surgery Specialty Hospitals of America, Pasadena, Texas, United States
Other microbiome trials you might be interested in
Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerHR+/HER2- Ductal and Lobular Breast CancerTriple Negative Breast CancerColorectal Cancer
The purpose of this study is to evaluate the safety, tolerability, dosimetry and preliminary efficacy of \[177Lu\]Lu-NNS…
Birmingham, United StatesEst. completion Jan 15, 2031
Acute-on-Chronic Liver Failure (ACLF)Liver CirrhosisEnd Stage Liver Disease
Acute-on-chronic liver failure (ACLF) is a serious condition where a patient with long-term liver disease suddenly exper…
Multiple LocationsEst. completion Aug 2027
Bladder AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Mixed AdenocarcinomaBladder Neuroendocrine CarcinomaBladder Small Cell Neuroendocrine CarcinomaBladder Squamous Cell CarcinomaChromophobe Renal Cell CarcinomaCollecting Duct CarcinomaInvasive Bladder Giant Cell Urothelial CarcinomaInvasive Bladder Lymphoepithelioma-Like CarcinomaInvasive Bladder Nested Urothelial CarcinomaInvasive Bladder Plasmacytoid Urothelial CarcinomaInvasive Bladder Sarcomatoid Urothelial CarcinomaInvasive Bladder Urothelial CarcinomaKidney Medullary CarcinomaLarge Cell Neuroendocrine CarcinomaMalignant Testicular Leydig Cell TumorMalignant Testicular Sertoli Cell TumorMetastatic Bladder CarcinomaMetastatic Bladder Clear Cell (Glycogen-Rich) Urothelial CarcinomaMetastatic Bladder Giant Cell Urothelial CarcinomaMetastatic Bladder Large Cell Neuroendocrine CarcinomaMetastatic Bladder Lipid-Rich Urothelial CarcinomaMetastatic Bladder Micropapillary Urothelial CarcinomaMetastatic Bladder Plasmacytoid Urothelial CarcinomaMetastatic Bladder Sarcomatoid Urothelial CarcinomaMetastatic Bladder Small Cell Neuroendocrine CarcinomaMetastatic Bladder Squamous Cell CarcinomaMetastatic Chromophobe Renal Cell CarcinomaMetastatic Kidney Medullary CarcinomaMetastatic Malignant Genitourinary System NeoplasmMetastatic Papillary Renal Cell CarcinomaMetastatic Penile CarcinomaMetastatic Prostate Small Cell Neuroendocrine CarcinomaMetastatic Sarcomatoid Renal Cell CarcinomaMetastatic Urethral CarcinomaPapillary Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage IV Bladder Cancer AJCC v8Stage IV Penile Cancer AJCC v8Stage IV Renal Cell Cancer AJCC v8Stage IV Urethral Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8Urachal AdenocarcinomaUrethral Clear Cell Adenocarcinoma
This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patient…
Birmingham, United StatesEst. completion Feb 28, 2027